CRISPR (CRSP) to Report Q1 Earnings: What’s in the Cards?
ZacksOn CRISPR Therapeutics’ (CRSP) first-quarter 2024 earnings call, investors’ focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.